Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Gains from Investment Securities (2020 - 2025)

Keros Therapeutics (KROS) has disclosed Gains from Investment Securities for 5 consecutive years, with $7.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 224.3% year-over-year to $7.1 million, compared with a TTM value of $7.1 million through Dec 2025, changed N/A, and an annual FY2025 reading of $7.1 million, changed N/A over the prior year.
  • Gains from Investment Securities was $7.1 million for Q4 2025 at Keros Therapeutics, up from -$5.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.1 million in Q4 2025 and bottomed at -$5.7 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $1.1 million, with a median of $663000.0 recorded in 2022.
  • The sharpest move saw Gains from Investment Securities surged 11283.33% in 2023, then crashed 527.5% in 2024.
  • Year by year, Gains from Investment Securities stood at -$26000.0 in 2021, then surged by 53.85% to -$12000.0 in 2022, then soared by 11283.33% to $1.3 million in 2023, then plummeted by 527.5% to -$5.7 million in 2024, then skyrocketed by 224.3% to $7.1 million in 2025.
  • Business Quant data shows Gains from Investment Securities for KROS at $7.1 million in Q4 2025, -$5.7 million in Q4 2024, and $5.7 million in Q3 2024.